RNAi-based therapeutics and tumor targeted delivery in cancer
Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …
for the development of targeted therapies for cancer and other diseases. The discovery of …
Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases
Abstract Central Nervous System (CNS) diseases, such as Alzheimer's diseases (AD),
Parkinson's Diseases (PD), brain tumors, Huntington's disease (HD), and stroke, still remain …
Parkinson's Diseases (PD), brain tumors, Huntington's disease (HD), and stroke, still remain …
[HTML][HTML] Engineered smart materials for RNA based molecular therapy to treat Glioblastoma
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that
remains incurable despite the multitude of improvements in cancer therapeutics. The …
remains incurable despite the multitude of improvements in cancer therapeutics. The …
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics
RNA therapeutics have emerged as next-generation therapy for the treatment of many
diseases. Unlike small molecules, RNA targeted drugs are not limited by the availability of …
diseases. Unlike small molecules, RNA targeted drugs are not limited by the availability of …
AKR1B1 represses glioma cell proliferation through p38 MAPK-mediated Bcl-2/BAX/Caspase-3 apoptotic signaling pathways
This study aimed to investigate the regulatory role of Aldo-keto reductase family 1 member
B1 (AKR1B1) in glioma cell proliferation through p38 MAPK activation to control Bcl …
B1 (AKR1B1) in glioma cell proliferation through p38 MAPK activation to control Bcl …
Decoding microRNA drivers in atherosclerosis
T Vartak, S Kumaresan, E Brennan - Bioscience reports, 2022 - portlandpress.com
An estimated 97% of the human genome consists of non-protein-coding sequences. As our
understanding of genome regulation improves, this has led to the characterization of a …
understanding of genome regulation improves, this has led to the characterization of a …
RNA in cancer immunotherapy: unlocking the potential of the immune system
W De Mey, A Esprit, K Thielemans, K Breckpot… - Clinical Cancer …, 2022 - AACR
Recent advances in the manufacturing, modification, purification, and cellular delivery of
ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a …
ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a …
The role of microRNAs in multidrug resistance of glioblastoma
Simple Summary Glioblastoma (GBM) is one of the most malignant types of central nervous
system tumor which accounts for more than 60% of all brain tumors in adults. Owing to poor …
system tumor which accounts for more than 60% of all brain tumors in adults. Owing to poor …
Treatment of human glioblastoma U251 cells with sulforaphane and a peptide nucleic acid (PNA) targeting miR-15b-5p: synergistic effects on induction of apoptosis
Glioblastoma multiforme (GBM) is a lethal malignant tumor accounting for 42% of the tumors
of the central nervous system, the median survival being 15 months. At present, no curative …
of the central nervous system, the median survival being 15 months. At present, no curative …
Peptide nucleic acids and their role in gene regulation and editing
JDR Perera, KEW Carufe, PM Glazer - Biopolymers, 2021 - Wiley Online Library
The unique properties of peptide nucleic acid (PNA) makes it a desirable candidate to be
used in therapeutic and biotechnological interventions. It has been broadly utilized for …
used in therapeutic and biotechnological interventions. It has been broadly utilized for …